P/E ratio for UroGen Pharma (URGN)
P/E ratio as of May 2024 (TTM): -2.82
According to UroGen Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.82265. At the end of 2022 the company had a P/E ratio of -1.86.
P/E ratio history for UroGen Pharma from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.86 | -3.22% |
| 2021 | -1.92 | -37.01% |
| 2020 | -3.04 | -53.3% |
| 2019 | -6.52 | -27.95% |
| 2018 | -9.05 | -55.59% |
| 2017 | -20.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.14 | 46.59% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.